Biocon Q1FY24 Revenue at Rs 3516 Cr, Up 59 Biosimilars Up ... - Biocon
| ALDBT Stock | EUR 0.43 0.01 2.38% |
Slightly above 54% of DBT SA's retail investors are presently thinking to get in. The analysis of current outlook of investing in DBT SA suggests that some traders are interested regarding DBT SA's prospects. DBT SA's investing sentiment overview a quick insight into current market opportunities from investing in DBT SA. Many technical investors use DBT SA stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
DBT |
Biocon Q1FY24 Revenue at Rs 3516 Cr, Up 59 Biosimilars Up ... Biocon
Read at news.google.com
 |
DBT SA Fundamental Analysis
We analyze DBT SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of DBT SA using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of DBT SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Sales
Price To Sales Comparative Analysis
DBT SA is currently under evaluation in price to sales category among its peers. Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
DBT SA Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with DBT SA stock to make a market-neutral strategy. Peer analysis of DBT SA could also be used in its relative valuation, which is a method of valuing DBT SA by comparing valuation metrics with similar companies.
Peers
DBT SA Related Equities
| ALDRV | Drone Volt | 2.94 | ||||
| ALBPS | Biophytis | 3.13 | ||||
| ALNOV | Novacyt | 3.13 | ||||
| ALNEV | Neovacs SA | 28.06 |
Additional Tools for DBT Stock Analysis
When running DBT SA's price analysis, check to measure DBT SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DBT SA is operating at the current time. Most of DBT SA's value examination focuses on studying past and present price action to predict the probability of DBT SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DBT SA's price. Additionally, you may evaluate how the addition of DBT SA to your portfolios can decrease your overall portfolio volatility.